|
[Related PubMed/MEDLINE]
Total Number of Papers: 45
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling. |
OATP, PKs, UGT |
| 2 |
2023 |
Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species. |
ADME, PK |
| 3 |
2023 |
Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. |
FDA, PKs, WHO |
| 4 |
2023 |
Quantitative Characterization of Clinically Relevant Drug-Metabolizing Enzymes and Transporters in Rat Liver and Intestinal Segments for Applications in PBPK Modeling. |
BCRP, DMETs, Mrp, OATP, PK, TPA, UGT |
| 5 |
2023 |
Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. |
PDs, PKs |
| 6 |
2022 |
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds. |
AAFE, AAPE, AFE, CL, ML, PK, Vss |
| 7 |
2022 |
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. |
ADME, ASGPR, PD, PK, siRNA |
| 8 |
2022 |
Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. |
IMPAACT, PK, RDV |
| 9 |
2022 |
Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. |
PK, RI, SGLT2, T2DM |
| 10 |
2022 |
Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues. |
devTOX qP, DTP, EADs, IVIVE, LELs, PK, VPA |
| 11 |
2021 |
A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. |
PK |
| 12 |
2021 |
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. |
CNS, CSF, ECF, LeiCNS-PK3.0, PK |
| 13 |
2021 |
Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. |
PD, PK, PopPK |
| 14 |
2021 |
Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population. |
NCA, PK |
| 15 |
2021 |
Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity. |
BNP, DIC |
| 16 |
2021 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture. |
DcNP, NHP, PK, TLC-ART |
| 17 |
2021 |
Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. |
DABE, DOACs, PKs |
| 18 |
2021 |
Population pharmacokinetic analysis of RO5459072, a low water-soluble drug exhibiting complex food-drug interactions. |
PK |
| 19 |
2021 |
Predicting human pharmacokinetics from preclinical data: volume of distribution. |
PK, Vd |
| 20 |
2021 |
Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. |
PK |
| 21 |
2021 |
Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. |
CGNM, PKs |
| 22 |
2020 |
A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates. |
PA, PK, TH |
| 23 |
2020 |
Physiologically based pharmacokinetic modelling of lisinopril in children: A case story of angiotensin converting enzyme inhibitors. |
PK |
| 24 |
2020 |
Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. |
ADME, NPs, PD, PK |
| 25 |
2020 |
Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States. |
DMET, PD, PK |
| 26 |
2019 |
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. |
AUC, DDIs, PK, TDI |
| 27 |
2019 |
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. |
CAR, PK-PD, TGI |
| 28 |
2019 |
Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis. |
BCS, IR, IVIVC, PK, PSA |
| 29 |
2019 |
Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion. |
OATPs, PK |
| 30 |
2018 |
Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. |
ADME, AUC, PKs |
| 31 |
2017 |
Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. |
ADCs, PK |
| 32 |
2017 |
Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation. |
PK |
| 33 |
2017 |
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. |
PK |
| 34 |
2017 |
Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. |
--- |
| 35 |
2016 |
Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels. |
PK |
| 36 |
2015 |
Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research. |
fuip, fup, PK/PD |
| 37 |
2015 |
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. |
ADME, FIH, mAbs, PD, PK, TMDD |
| 38 |
2015 |
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. |
PK |
| 39 |
2014 |
Biologics: an update and challenge of their pharmacokinetics. |
ADA, ADCs, ADME, DI, e.g. Fabs, FcgammaR, mAbs, PK, pop-PK, SMs, TMDD |
| 40 |
2013 |
Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. |
PK |
| 41 |
2013 |
Modeling bioavailability to organs protected by biological barriers. |
PK |
| 42 |
2012 |
Pharmacokinetic models for FcRn-mediated IgG disposition. |
--- |
| 43 |
2012 |
Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. |
ADME, IVIVE, PD, PK |
| 44 |
2012 |
Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. |
AUC, CYP3A4, i.v, PK, TDI |
| 45 |
2011 |
The impact of hepatic uptake on the pharmacokinetics of organic anions. |
PK |
|
A Search Service for Abbreviation / Long Form
